SynthesisBMC cardiovascular disorders2025
Diagnostic value of long noncoding RNAs MIAT and MALAT1 in coronary artery disease: a systematic review and diagnostic accuracy test meta-analysis.
Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Elevated Metastasis-Associated lung adenocarcinoma transcript 1 (MALAT1) expression predicts coronary artery disease severity as a potential biomarker for risk stratification: a cross-sectional study.Annals of medicine · 2026Article
- Review
- Echoes in the powerhouse: mito-lncRNAs contribution to cardiac function and disease.Acta pharmacologica Sinica · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLong noncoding RNAs (lncRNAs) MALAT1 and MIAT modulate atherosclerotic progression and myocardial ischemia injury, through vascular endothelial dysfunction. Diagnostic values of these lncRNAs in detecting coronary artery disease (CAD) have been investigated, but the results have been inconsistent. We aimed to evaluate the diagnostic accuracy of lncRNAs MALAT1 and MIAT.
methodsA comprehensive search was done to identify case-control studies reporting diagnostic measures of MIAT and MALAT1 in patients with CAD compared to healthy controls. Methodological quality of included studies was assessed using the QUADAS-2 checklist. All analyses were conducted in R software. Hierarchical models were applied to pooled diagnostic performance metrics. We used the “meta” package to estimate the odds ratio (OR) for MALAT1, and to pool sensitivity and specificity for both lncRNAs. We also used the “mada” package to estimate the positive likelihood ratio (PLR), negative likelihood ratio (NLR), area under the receiver operating characteristic curve (AUC), and diagnostic odds ratio (DOR). Meta-regression analyses based on mean age and male percentage were conducted to explore potential sources of heterogeneity.
resultsTen studies were included, encompassing a total of 1,879 individuals (1009 CAD cases and 870 healthy controls) with a mean age of 59.24 years. The diagnostic performance of lncRNA MALAT1 showed a pooled sensitivity of 0.68 and specificity of 0.70, with an AUC of 0.746 and a DOR of 5.17 (95% CI: 2.26–11.85), showing acceptable diagnostic power. For lncRNA MIAT, the pooled sensitivity and specificity were 0.81 and 0.65, respectively, with an AUC of 0.757 and a DOR of 7.64 (95% CI: 2.12–27.47), indicating moderate accuracy. The prognostic value of MALAT1 in CAD was assessed, showing a significant association with disease outcomes (OR = 2.81, 95% CI: 1.04–7.56).
conclusionsThis study indicates that both MALAT1 and MIAT demonstrate moderate diagnostic accuracy for CAD, with limitations in their clinical utility. MALAT1 also appears to have prognostic potential, suggesting its broader clinical relevance. Further research in standardized clinical settings is needed to validate these findings and clarify their practical applications in CAD diagnosis and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.